1 min read
Valsartan is a well-known prescription medication used to treat hypertension and other cardiac problems. However, it was determined that certain components used in the production of Valsartan were compromised with NDMA. Furthermore, human cancer has been linked to NDMA (N-nitroso dimethylamine). The FDA and European health regulators responded by issuing global safety recalls of the contaminated Valsartan products. 
Valsartan suits are currently consolidated in MDL-2875 presided over by Robert B. Kugler (Sr. District Judge) in New Jersey. As of February 16, 2023, there are 1,197 pending cases. 
Following the recent rejection of all Zantac claims due to a lack of reliable causation evidence, the Valsartan defendants filed a motion asking the MDL Judge to reconsider his former finding on expert evidence admission. The defendants hoped that the Valsartan charges would be dismissed on the same grounds. Nevertheless, in an Order released last week, Judge Kugler denied the motion, paving the path for the Valsartan litigation to proceed. Judge Kugler said that because the Valsartan instances included different circumstances than the Zantac litigation, the legal grounds for dismissal were inapplicable. This indicates that the Valsartan cases will be tried as soon as possible. 
Michael Brady Lynch Firm
Here at the Michael Brady Lynch firm, we handle strict product liability cases. If you or a loved one has been injured by Valsartan, please give us a call at 888-585-5970.
Date: Feb 20, 2023
Author: Brandon Salter